118 related articles for article (PubMed ID: 15685732)
21. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
22. NNRTIs: a neglected class.
Cadman J
GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
[TBL] [Abstract][Full Text] [Related]
23. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
[TBL] [Abstract][Full Text] [Related]
24. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
[TBL] [Abstract][Full Text] [Related]
25. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
[TBL] [Abstract][Full Text] [Related]
26. Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.
González de Requena D; Gallego O; Corral A; Jiménez-Nácher I; Soriano V
AIDS; 2004 Oct; 18(15):2091-4. PubMed ID: 15577634
[TBL] [Abstract][Full Text] [Related]
27. In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Gianotti N; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Castagna A
New Microbiol; 2004 Apr; 27(2 Suppl 1):111-7. PubMed ID: 15646073
[TBL] [Abstract][Full Text] [Related]
28. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
29. [Efavirenz--comprehensive status of studies].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
[No Abstract] [Full Text] [Related]
30. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
Imaz A; Podzamczer D
AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
[TBL] [Abstract][Full Text] [Related]
31. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.
Grossman Z; Istomin V; Averbuch D; Lorber M; Risenberg K; Levi I; Chowers M; Burke M; Bar Yaacov N; Schapiro JM;
AIDS; 2004 Apr; 18(6):909-15. PubMed ID: 15060438
[TBL] [Abstract][Full Text] [Related]
32. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
[TBL] [Abstract][Full Text] [Related]
33. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
[TBL] [Abstract][Full Text] [Related]
34. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
Jayaweera D; Dilanchian P
Expert Opin Pharmacother; 2012 Dec; 13(18):2601-12. PubMed ID: 23176566
[TBL] [Abstract][Full Text] [Related]
35. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
36. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination.
James JS
AIDS Treat News; 1998 Jul; (No 299):1-3. PubMed ID: 11365599
[TBL] [Abstract][Full Text] [Related]
37. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Parienti JJ; Massari V; Descamps D; Vabret A; Bouvet E; Larouzé B; Verdon R
Clin Infect Dis; 2004 May; 38(9):1311-6. PubMed ID: 15127346
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
[TBL] [Abstract][Full Text] [Related]
39. Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.
Winters MA; Kagan RM; Kovari L; Heseltine PN; Merigan TC
Antivir Ther; 2005; 10(2):363-6. PubMed ID: 15865232
[TBL] [Abstract][Full Text] [Related]
40. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]